

# Mouse CD300g/Nepmucin Alexa Fluor® 350-conjugated

Antigen Affinity-purified Polyclonal Sheep IgG

Catalog l	Number:	AF5554U
_		100 ua

DESCRIPTION	
Species Reactivity	Mouse
Specificity	Detects mouse CD300g/Nepmucin in direct ELISAs and Western blots. In direct ELISAs, less than 1% cross-reactivity with recombinant human CD300g/Nepmucin is observed.
Source	Polyclonal Sheep IgG
Purification	Antigen Affinity-purified
Immunogen	Mouse myeloma cell line NS0-derived recombinant mouse CD300g/Nepmucin Leu19-Ile284 Accession # NP_001154183
Conjugate	Alexa Fluor 350 Excitation Wavelength: 346 nm Emission Wavelength: 442 nm
Formulation	Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide
	*Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

#### **APPLICATIONS**

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Western Blot Optimal dilution of this antibody should be experimentally determined.

China | info.cn@bio-techne.com TEL: 400.821.3475

### PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

#### **BACKGROUND**

Nepmucin (a not expressed in Peyer's Patch mucin; also CLM-9, CD300g and TREM4) is a member of the CD300L family of proteins. It is expressed on endothelium and serves multiple functions. It is known to form homotypic interactions between endothelial cells, bind lymphocytes via its Ig-like and mucin domains and serve as a transcellular transport vehicle for IgA and IgM. Mature mouse Nepmucin is a 397 amino acid (aa) type I transmembrane glycoprotein. Its extracellular region (aa 19-288) contains one V-type Ig-like domain (aa 19-124) plus an O-glycosylated mucin region (aa 136-276). There are at least three isoform variants. One is 60-75 kDa in size and shows an Ala substitution for aa 126-170, a second is 46-50 kDa in size and shows an Arg substitution for aa 170-254, while a third is 36 kDa in size and shows a SerTyr substitution for aa 134-256. Over aa 1-284, mouse Nepmucin shares 89% and 53% aa identity with rat and human Nepmucin, respectively.

## PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

Rev. 9/16/2025 Page 1 of 1